Clinical Trials
2 trialsNCT00630110 2011-08-16
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Nereus Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00322608 2011-01-10
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Nereus Pharmaceuticals, Inc.
Phase 1 Completed